



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q3

2023

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

October 26, 2023

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q3 2023

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Specialty Chemicals shifts EBITDA above prior year / guidance adjusted



Continuous effort to establish Alzchem more and more as a Specialty Chemicals company



Operating cash flow and free cash flow strongly positive and much higher compared to last year



Additional expansion of Creapure® capacities on schedule with expected completion in fall 2023



EBITDA is much higher than previous year while sales are slightly lower



Guidance adjusted with EBITDA increase to approx. 80m EUR; sales at previous year level



Human nutrition market contributes significantly to growth

MARKETS DEVELOPMENTS

Consistent focus on the high-margin Specialty Chemicals business



BASICS & INTERMEDIATES




PHARMA EU



METALLURGY


SPECIALTY CHEMICALS



HUMAN NUTRITION




ANIMAL
NUTRITION



AUTOMOTIVE
/DEFENSE




PHARMA RoW




AGRICULTURE
(FERTILIZER)



FINE
CHEMICALS



AGRICULTURE




CUSTOM
SYNTHESIS

OUTLOOK 2023 (in M€)


Outlook adjusted; EBITDA strong growth



SALES



EBITDA




COMMENTS

- Outlook 2023 adjusted for the first time this year
- Group sales are expected to end up at prior year level or slightly below
 - Lower volumes in Basics & Intermediates with higher impact than sales growth in Specialty Chemicals
- EBITDA is expected to end up at around 80 M€
 - Transformation to more sales in Specialty Chemical with high-margin products supports EBITDA increase
 - Avoidance of price competition and low margin sales in Basics & Intermediates lead to positive impact on EBITDA
- EBITDA-Margin also with development of sales and EBITDA → expected to grow noticeably
- Inventory level and inventory ratio are expected to decrease slightly to significantly based on lower price levels and lower carbide production
- Equity ratio expected to grow significantly due to positive net result and interest increase on pension valuation


"VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Ability to adapt production to meet changing end market needs



"VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Health & Nutrition



Premium brand for creatine monohydrate as a food supplement in sports nutrition



Dietary supplement with pure creatine



Creatine for health and food applications




HEALTH & NUTRION MARKET

Creatine – what is the hype all about?



- Creatine is a substance produced naturally in the body.
- A good portion of creatine in the body is stored as phosphocreatine.
- Phosphocreatine is the bridge between spontaneous ATP energy and extra cellular energy deposits.
- Like a battery, phosphocreatine supplies, recycles and buffers energy, making it instantly available when needed.
- Phosphocreatine is also a transporter of cellular energy.



HEALTH & NUTRION MARKET

Daily creatine supply and sources




CREATINE SUPPLY

- Approx. 50–60% of creatine demand is typically produced endogenously
- Food sources for creatine are all animal based
- Daily optimum level can be reached either by:
 - 600g raw meat
 - 600g raw fish
 - 30 liters of milk
 - **or 3g creatine supplementation**

CREATINE TURNOVER

- The human body contains approx 80-120g creatine
- 1–3% are „used up“ per day
- Authorities confirm the effects of 3–5g creatine per day*

* based on scientific studies and two EU-Health Claims



FINANCIAL OVERVIEW

Positive profitability performance in a challenging environment



Alzchem Group	Q3 2022	Q3 2023	yoy %	2022 1 - 9	2023 1 - 9	yoy %
SALES (in M€)	139.2	120.8	-13.2%	409.0	397.9	-2.7%
EBITDA (in M€)	12.1	19.5	+60.8%	47.0	56.3	+19.8%
EBITDA margin (in %)	8.7%	16.2%	+7.4 pp	11.5%	14.2%	+2.7 pp
Earnings per Share (in €)	0.59	0.85	+44.5%	2.29	2.31	+0.9%

- Sales in first nine months slightly lower than previous year (3%) with different segment development. Specialty still on growth path but Basics & Intermediates lost volume.
- Sales switch into Specialty Chemicals leads to increased EBITDA (+9m €) and better EBITDA-margin with major impact in Q3
- Energy and raw material costs still high but stable development supports stable pricing strategy without major jumps as seen in last year
- Last years capex in Human-Nutrition market pays off and contributes significantly to growth

SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	-12.8%	-12.8%
Price	1.1%	10.3%
Currency	-1.5%	-0.3%

AGENDA – ANALYST PRESENTATION Q3 2023

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Volume reductions but increased EBITDA


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	- 21.4%	- 24.1%
Price	- 3.5%	+ 8.7%
Currency	- 0.7%	- 0.2%

COMMENTS

- Q3/2023 sales ~ 26 % below previous year as a combination of volume and price reductions
- Persistently high energy prices led to necessary price increases in agricultural and pharmaceutical sector which cannot keep pace with Asian competitors
- Alzchem consequently avoids low margin business and willingly accepts lower volumes
- Metallurgic sector sales slightly under previous year's
- EBITDA-Margin increased to 4.2 % in 2023 (previous year 0.6 %)
- More stable - albeit very high - electricity prices had a positive effect on EBITDA in addition with the discontinuation of lower-margin business compared to previous year



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)




2023 Sales and EBITDA growth continued and caused outlook increase


SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	- 7.2%	- 5.5%
Price	+ 4.7%	+ 12.3%
Currency	- 2.2%	- 0.3%

COMMENTS

- Specialty Chemicals with more and more significance
- 2023 sales are 6.5% higher than previous year
- The capacity expansion at Creapure® leads to more than doubling of sales compared to the previous year with major contribution to EBITDA growth
- Creamino® and guanidine salts with partially high sales increases
- Slightly lower volumes in BioSelect®, which suffers from high stock levels – and DYHARD® which suffers from the general development within the chemical industry
- EBITDA improved in line with sales growth
- 2023 EBITDA-Margin of +21.7 % (previous year+21.1 %)



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)




Development of services in line with costs pass-through


SALES




EBITDA



SALES



EBITDA



COMMENTS


- 2023 sales are ~11 % above previous year's level based on pass-through of cost increases in pricing and higher grid fees in energy supply services
- Costs for internal technical supply and network costs that cannot be passed on to customers led to a small decline in EBITDA

BALANCE SHEET (in M€)


Stable balance sheet development with improved equity ratio



ASSETS



LIABILITIES




- Total assets increased since last period driven by development of current assets
- Cautious investment activities led to a slight decline in non-current assets
- Current assets increased as a result of slight increase in stock levels and increased trade receivables
- Scheduled plant shut-downs led to planned increased stock levels prior to shut-down; trade receivables are mainly impacted by factoring decrease

- Equity ratio improved to 37.6%
- Net income and interest rates on pension obligations had a positive impact on equity, while dividend payment of 10.7 M€ reduced equity.
- Pension obligation decreased mainly as a result of interest increases up to 4.0%
- The restructuring of financing loans from current to non-current (30.0 M€) leads the increase of non-current liabilities, while the current-liabilities decrease

CASHFLOW (in M€)

Strong operating and free cashflow; reduction of short-term financing



- Very strong cashflow from operating activities in first nine month of 2023 (+ 44.7 M€) due to strict working capital management – increase of 58.8 M€ compared to last year
- Cashflow from investing activity characterized by the cautious investment policy in 2023. Nevertheless no slowdown in investing in capacity expansions of the Creapure® -plant and renewal of the grid operations
- Further investment projects already decided or under discussion

- Free cashflow also strongly increased compared to prior year -> increase of 66.8 M€; all investments were financed by operating cashflow and additional amounts used to reduce short-term financing lines
- Cashflow from financing activities was marked by the restructuring of financing loans from current to non-current (30.0 M€)

FINANCIAL CALENDAR

Upcoming dates*



NOV 15	2023	Münchner Kapitalmarkt Konferenz 2023
NOV 27 – 29	2023	Deutsches Eigenkapitalforum 2023
MAR 1	2024	Annual Report
APR 30	2024	Quarterly Statement 1 st Quarter 2024
MAY 7	2024	Annual General Meeting
AUG 1	2024	Quarterly Statement 2 nd Quarter 2024
NOV 7	2024	Quarterly Statement 4 th Quarter 2024

*subject to change

FEEDBACK

We appreciate your feedback



Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q3 2023

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2022	30.09.2023	Deviation	
Intangible assets	2,954	3,237	283	9.6%
Tangible assets	181,526	176,435	-5,091	-2.8%
Investment properties				
Right of use (assets)	6,250	5,132	-1,118	-17.9%
Investments accounted for using the equity method				
Financial assets	6	6		
Trade receivables				
Other receivables	1,531	1,538	7	0.5%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	15,956	15,218	-737	-4.6%
SUM NON-CURRENT ASSETS	208,223	201,566	-6,656	-3.2%
Inventories	122,404	125,269	2,865	2.3%
Trade receivables	55,712	63,069	7,357	13.2%
Financial assets	5,228	1,748	-3,480	-66.6%
Other receivables	19,743	17,927	-1,815	-9.2%
Income tax receivables	2,307	2,817	510	22.1%
Cash and cash equivalents	9,243	16,732	7,489	81.0%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	214,638	227,563	12,926	6.0%
SUM ASSETS	422,860	429,130	6,269	1.5%

ALZCHEM GROUP (IN T€)	31.12.2022	30.09.2023	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	121,044	133,837	12,793	10.6%
Other comprehensive income	-15,316	-12,742	2,574	-16.8%
Own shares	-1,009		1,009	-100.0%
SHARE TO THE SHAREHOLDERS	144,012	159,379	15,367	10.7%
Non-controlling interests	1,934	2,063	128	6.6%
SUM EQUITY	145,947	161,442	15,495	10.6%
Provisions for pensions	90,141	87,428	-2,712	-3.0%
Other provisions	17,011	17,155	144	0.8%
Loans	27,498	50,873	23,375	85.0%
Finance lease liabilities	4,622	3,684	-938	-20.3%
Trade liabilities				
Other liabilities	171		-171	-100.0%
Deferred tax liabilities	5,365	6,265	900	16.8%
SUM NON-CURRENT LIABILITIES	144,808	165,405	20,598	14.2%
Other provisions	1,944	2,144	200	10.3%
Loans	66,408	32,437	-33,971	-51.2%
Finance lease liabilities	1,707	1,581	-125	-7.3%
Finance liabilities				
Trade liabilities	37,386	29,018	-8,369	-22.4%
Other liabilities	23,060	33,563	10,503	45.5%
Income tax liabilities	1,602	3,540	1,938	121.0%
SUM CURRENT LIABILITIES	132,106	102,282	-29,824	-22.6%
Sum EQUITY AND LIABILITIES	422,860	429,130	6,269	1.5%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates were increased from 3.7% to 4.0% leading to a net pension reduction of 2.9 M€
- All other actuarial assumptions are unchanged since December 31st, 2022
- Pension payments on expected level with 1.4 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Deviation (Q3)	
Revenue	129,395	140,435	139,193	133,200	150,432	126,599	120,824		-18,370	-13%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	14,144	14,467	-1,959	-4,459	916	9,105	147		2,106	-108%
Other income	4,070	5,736	5,955	8,416	5,574	1,906	3,104		-2,851	-48%
Raw materials and consumables used	-73,537	-74,027	-75,308	-66,006	-76,159	-62,374	-48,544		26,764	-36%
Employee benefits expense	-34,000	-36,287	-31,316	-35,537	-35,262	-36,012	-34,678		-3,363	11%
Other expense	-23,003	-32,517	-24,418	-21,198	-26,583	-21,352	-21,317		3,101	-13%
EBITDA	17,070	17,807	12,149	14,416	18,917	17,872	19,534		7,386	61%
Depreciation expense	-6,305	-6,299	-6,324	-6,616	-6,320	-6,335	-6,574		-250	4%
Impairment										
EBIT	10,765	11,508	5,825	7,800	12,598	11,537	12,960		7,135	123%
Investment income										
Other interest and similar income	1,181	2,393	2,466	2,380	49	106	661		-1,805	-73%
Other interest and similar expense	-603	-643	-753	-1,037	-1,882	-1,661	-1,586		-833	111%
Financial result	578	1,750	1,713	1,343	-1,832	-1,555	-925		-2,638	-154%
Result from associates										
Result from ordinary business	11,343	13,258	7,538	9,143	10,765	9,982	12,035		4,497	60%
Taxes on income and profit	-3,603	-3,629	-1,559	-2,269	-3,055	-2,742	-3,379		-1,820	117%
<i>thereof income tax</i>	-2,520	-2,094	-842	562	-2,946	-2,716	-3,015		-2,173	258%
<i>thereof change from deferred taxes</i>	-1,082	-1,535	-717	-2,831	-109	-26	-364		353	-49%
Annual result	7,740	9,630	5,979	6,874	7,710	7,240	8,656		2,677	45%
<i>thereof minority interests</i>	43	43	43	43	43	43	43			
<i>thereof shares held by shareholders</i>	7,698	9,587	5,936	6,831	7,667	7,197	8,613		2,677	45%
Result per share in EUR	0.76 €	0.95 €	0.59 €	0.67 €	0.75 €	0.71 €	0.85 €			

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue
Increase (+) / Decrease (-) in inventories of finished goods and work in progress
Other income
Raw materials and consumables used
Employee benefits expense
Other expense
EBITDA
Depreciation expense
Impairment
EBIT
Investment income
Other interest and similar income
Other interest and similar expense
Financial result
Result from associates
Result from ordinary business
Taxes on income and profit
<i>thereof income tax</i>
<i>thereof change from deferred taxes</i>
Annual result
<i>thereof minority interests</i>
<i>thereof shares held by shareholders</i>
Result per share in EUR

Q3 2022	Q3 2023	Deviation (QoQ)	
139,193	120,824	-18,370	-13.2%
-1,959	147	2,106	-107.5%
5,955	3,104	-2,851	-47.9%
-75,308	-48,544	26,764	-35.5%
-31,316	-34,678	-3,363	10.7%
-24,418	-21,317	3,101	-12.7%
12,149	19,534	7,386	60.8%
-6,324	-6,574	-250	4.0%
0	0	0	
5,825	12,960	7,135	122.5%
0	0	0	
2,466	661	-1,805	-73.2%
-753	-1,586	-833	110.6%
1,713	-925	-2,638	-154.0%
0	0	0	
7,538	12,035	4,497	59.7%
-1,559	-3,379	-1,820	116.7%
-842	-3,015	-2,173	257.9%
-717	-364	353	-49.2%
5,979	8,656	2,677	44.8%
43	43	0	0.0%
5,936	8,613	2,677	45.1%
0.59 €	0.85 €	0	44.5%

YTD Sep.2022	YTD Sep.2023	Deviation (YoY)	
409,023	397,854	-11,168	-2.7%
26,652	10,168	-16,484	-61.8%
15,761	10,583	-5,178	-32.9%
-222,871	-187,077	35,794	-16.1%
-101,602	-105,953	-4,350	4.3%
-79,938	-69,252	10,685	-13.4%
47,025	56,324	9,299	19.8%
-18,927	-19,229	-302	1.6%
0	0	0	
28,098	37,095	8,997	32.0%
0	0	0	
6,041	816	-5,225	-86.5%
-1,999	-5,129	-3,129	156.5%
4,042	-4,312	-8,354	-206.7%
0	0	0	
32,139	32,782	643	2.0%
-8,790	-9,176	-386	4.4%
-5,456	-8,677	-3,221	59.0%
-3,334	-499	2,835	-85.0%
23,349	23,606	257	1.1%
128	128	0	0.0%
23,221	23,478	257	1.1%
2.29 €	2.31 €	0	0.9%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q3 2022	Q3 2023	1 - 9 2022	1 - 9 2023
Consolidated earnings before taxes	7,538	12,035	32,139	32,782
Depreciation on fixed and intangible assets	6,324	6,574	18,927	19,229
Decrease in pension provisions	-375	-441	-1,253	-1,408
Loss (+) / Profit (-) from the sale of non-current assets	0	-8	-58	-9
Other non-cash income (-) and expenses (+)	966	837	2,802	3,751
Financial result	-1,713	925	-4,042	4,312
Interests & Taxes	-2,406	-4,068	-6,195	-9,513
Increase (+) / Decrease (-) Net Working Capital	-7,263	-10,964	-56,420	-4,440
Cashflow from ongoing operations (Net cash flow)	3,070	4,890	-14,099	44,705
Cash outflows for investments in fixed assets	-7,662	-5,653	-22,743	-14,230
Cash inflows from the sale of fixed assets	0	8	61	9
Cash inflows from the disposal of investments	484		484	
Cashflow from investing activity	-7,177	-5,645	-22,198	-14,222
Free cashflow	-4,106	-755	-36,296	30,483
Deposits (+) / Repayment (-) bank loans long-term				30,000
Repayment of bank loans long-term	-2,514	-1,735	-7,976	-6,762
Deposits (+) / Repayment (-) from short-term financing lines	6,294	10,170	56,956	-33,863
Dividend payments			-10,136	-10,685
Payment of reduction in leasing liabilities	-470	-435	-1,411	-1,331
Payments for the acquisition of own shares (incl. transaction costs)				
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	3,310	8,000	37,263	-22,813
Net increase / decrease in cash and cash equivalents	-797	7,245	966	7,670

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

SALES	2021				2022				2023				Deviation PY (Q3)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	41,070	45,178	42,465	47,561	57,441	57,927	59,557	52,614	57,337	46,038	44,271		-15,286	-26%
Specialty Chemicals	56,775	59,330	47,116	57,279	65,279	76,214	72,967	73,902	85,783	73,172	69,545		-3,421	-5%
Other and Holding	6,477	6,492	6,339	6,212	6,675	6,294	6,670	6,684	7,312	7,389	7,007		337	5%
Group Consolidation														
Alzchem Group	104,321	111,000	95,920	111,052	129,395	140,435	139,193	133,200	150,432	126,599	120,824		-18,370	-13%

EBITDA

EBITDA	2021				2022				2023				Deviation PY (Q3)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	2,791	3,826	3,118	1,250	2,841	853	-2,621	3,910	2,780	2,410	1,065		3,687	141%
Specialty Chemicals	13,947	14,801	10,096	11,820	14,267	16,322	14,637	7,789	16,019	14,936	18,541		3,904	27%
Other and Holding	435	-43	512	502	-139	830	1,038	230	475	438	721		-317	-31%
Group Consolidation	-451	409	112	-1,079	103	-200	-905	2,487	-357	88	-793		112	12%
Alzchem Group	16,722	18,993	13,838	12,493	17,072	17,805	12,149	14,416	18,917	17,872	19,534		7,386	61%

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

BEI ALZCHEM SEIT 1999

RESSORTVERANTWORTUNG

Finanzen & Controlling,
Unternehmensstrategie, Investor
Relations & Kommunikation, Risk
Management, Personal, IT, Supply
Chain Management,
Recht/Patente & Marken

DR. GEORG WEICHSELBAUMER

CSO

BEI ALZCHEM SEIT 2012

RESSORTVERANTWORTUNG

Marketing, Vertrieb,
Innovationsmanagement &
Verfahrensentwicklung, F&E,
Produktsicherheit /-zulassung

KLAUS ENGLMAIER

COO


BEI ALZCHEM SEIT 1988

RESSORTVERANTWORTUNG

Produktion, Engineering,
Umweltschutz/Sicherheit/Ges
undheit/Qualität, Technik


ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES		Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
		Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
		Reduction of methane emissions during storage of manure	Agriculture
		Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Raw material price increases at least passed on to the market
- Flexibilization of production
- Reduce waste via development of new processes (Creapure®)

GROWTH

- Volume growth and full utilization of realized capex (Creapure®, Creamino®, Nitralz®, SiliconNitride)
- Establish Eminex® as a methane prevention product
- Initiate and decide on capacity expansion of MultiPurpose plants

SUSTAINABILITY

- Vision 0 accidents and 0 waste
- Implementation of climate roadmap (with reduction of CO₂ and water footprint (-10%))
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner


KEY SHARE DATA

Share Details as of October 24, 2023



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 19.55
MARKET CAPITALIZATION	EUR 199 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



As of April 2023. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices”.